top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
18 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
18 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Novartis Announces Positive Results for Zolgensma Trial in Older Children with Spinal Muscular Atrophy
Novartis's gene therapy, Zolgensma, is already approved in the U.S. for children under the age of two with spinal muscular atrophy (SMA), a severe genetic disorder that affects the muscles and is the leading genetic cause of infant mortality. Now, the treatment has the potential to expand its use to older children, following promising results from a late-stage trial. The trial focused on patients aged 2 to less than 18 who had never received prior treatment and were unable to
Jan 4, 2025


StitchR: New Technology for Treating Genetic Diseases with Large Genes
Gene therapy has shown promise in treating many genetic diseases, but some conditions, like muscular dystrophy, involve very large genes that are too big to be delivered using current methods. A new technology called StitchR has solved this problem and could offer a treatment option for these hard-to-treat conditions. Instead of trying to deliver the whole large gene at once, StitchR splits the gene into two smaller parts. These two parts are delivered separately into cells,
Nov 18, 2024


AI Creates Precise DNA “Switches” for Gene Therapy - A Step Closer to Targeted Treatments
Imagine controlling genes with the precision of a light switch— controlling specific parts of the body as you will. That’s what the researchers at Yale, Jackson Laboratory, and the Broad Institute aimed to achieved with a new AI tool called CODA (Computational Optimization of DNA Activity). This newly designed AI tool creates custom DNA “switches” that control when and where genes turn on or off, which could greatly improve gene therapy. What is CODA? CODA is a groundbreaking
Oct 23, 2024


Penn Medicine Studies on AAV-based Gene Therapies Suggest Integration into Human DNA is Unlikely to Drive Cancer Mutations
Penn Medicine research offers promising insights into AAV-based gene therapies' safety: Integration into human DNA is unlikely to trigger cancer mutations. A recent study from the University of Pennsylvania’s Gene Therapy Program, published in Nature Biotechnology and Human Gene Therapy, analyzed AAV-based gene therapies in non-human primates. This study suggests that the integration of AAV vectors into chromosomal DNA, if it occurs, is unlikely to induce cancer-causing mutat
Mar 1, 2024
bottom of page


